Publications

Belaunzarán-Zamudio P.F., Mateja A., Guerra-de-Blas P.D.C., Rincón-León H.A., Navarro-Fuentes K., Ruiz-Hernández E., Caballero-Sosa S., Camas-Durán F., Priego-Smith Z., Nájera-Cancino J.G., López-Roblero A., Trujillo-Murillo K.D.C., Powers J.H., Hunsberger S., Siddiqui S., Beigel J.H., Valdés-Salgado R., and Ruiz-Palacios G. (2021).

Comparison of clinical characteristics of Zika and dengue symptomatic infections and other acute illnesses of unidentified origin in Mexico.

Belaunzarán-Zamudio P.F., Ortega-Villa A.M., Mimenza-Alvarado A.J., Guerra-de-Blas P.D.C., Aguilar-Navarro S.G., Sepúlveda-Delgado J., Hunsberger S., Valdés-Salgado R., Ramos-Castañeda J., Rincón León H.A., Rodriguez de La Rosa P., Nájera Cancino J.G., Beigel J., Caballero Sosa S., Ruiz Hernández E., Powers J.H., Ruiz-Palacios G.M., and Lane C. (2021).

Comparison of the impact of Zika and dengue virus infection, and other acute illnesses of unidentified origin on cognitive functions in a prospective cohort in Chiapas Mexico.

Belaunzarán-Zamudio P.F., Rincón León H.A., Caballero Sosa S., Ruiz E., Nájera Cancino J.G., Rodriguez de La Rosa P., Guerrero Almeida M.L., Powers J.H., Beigel J.H., Hunsberger S., Trujillo K., Ramos P., Arteaga-Cabello F.J., López-Roblero A., Valdés-Salgado R., Arroyo-Figueroa H., Becerril E., and Ruiz-Palacios G. (2021).

Different epidemiological profiles in patients with Zika and dengue infection in Tapachula, Chiapas in Mexico (2016–2018): An observational, prospective cohort study.

Tucker J.D., Iwelunmor J., Abrams E., Donenberg G., Wilson E.C., Blachman-Demner D., Laimon L., Taiwo B.O., Kuhns K.M., John-Stewart G.C., Kohler P., Subramanian S., Ayieko J., Gbaja-Biamila T., Oladele D., Obiezu-Umeh C., Chima K.P., Jalil E.M., Falcao J., Ezechi O.C., and Kapogiannis B.G. (2021).

Accelerating adolescent HIV research in LMICs: The NICHD HIV prevention and treatment through a comprehensive care continuum (PATC3H) consortium.

Monroe A.K., Levy M.E., Greenberg A.E., Keruly J.C., Moore R.D., Horberg M.A., Kulie P., Mohanraj B.S., Kumar P.N., and Castel A.D. (2021).

Integrase inhibitor prescribing disparities in the DC and Johns Hopkins HIV cohorts.

Koay W.L.A., Dirajlal-Fargo S., Levy M.E., Kulie P., Monroe A., Castel A.D., and Rakhmanina N.Y. (2021).

Integrase strand transfer inhibitors and weight gain in children and youth with perinatal human immunodeficiency virus in the DC cohort.

Aschengrau A., Mussi-Pinhata M.M., Moye J., Chakhtoura N., Patel K., Williams P.L., Karalius B., Garvie P.A., Monte D., Whalen F., Lebov J., and Seage G.R. (2021).

An international prospective cohort study of HIV and Zika in infants and pregnancy (HIV ZIP): Study protocol.

Golmard L., Vasta L.M., Duflos V., Corsini C., d'Enghien C.D., McMaster M.L., Harney L.A., Carr A.G., Ling A., Dijoud F., Gauthier A., Miettinen M., Cost N.G., Gauthier-Villars M., Orbach D., Irtan S., Haouy S., Schultz K.A., Stoppa-Lyonnet D., Coupier I., Stewart D.R., and Sirvent N. (2021).

Testicular Sertoli cell tumour and potentially testicular Leydig cell tumour are features of DICER1 syndrome.

Mirshahi U.L., Kim J., Best A.F., Chen Z.E., Hu Y., Haley J.S., Golden A., Stahl R., Manickam K., Carr A.G., Harney L.A., Field A., Hatton J., Schultz K.A.P., Bauer A.J., Hill D.A., Rosenberg P.S., Murray M.F., Carey D.J., and Stewart D.R. (2021).

A genome-first approach to characterize DICER1 pathogenic variant prevalence, penetrance, and phenotype.

Vasta L.M., Khan N.E., Higgs C.P., Harney L.A., Carr A.G., Harris A.K., Schultz K.A.P., McMaster M.L., and Stewart D.R. (2021).

Hematologic indices in individuals with pathogenic germline DICER1 variants.

Vasta L.M., McMaster M.L., Harney L.A., Ling A., Kim J., Harris A.K., Carr A.G., Damrauer S.M., Rader D.J., Kember R.L., Kanetsky P.A., Nathanson K.L., Pyle L.C., Greene M.H., Schultz K.A., and Stewart D.R. (2020).

Lack of pathogenic germline DICER1 variants in males with testicular germ-cell tumors.

Merideth M.A., Harney L.A., Vyas N., Bachi A., Carr A.G., Hill D.A., Dehner L.P., Schultz K.A., Stewart D.R., and Stratton P. (2020).

Gynecologic and reproductive health in patients with pathogenic germline variants in DICER1.

Anderson C., Nichols H., House M., and Sandler D.P. (2019).

Risk versus benefit of chemoprevention among raloxifene and tamoxifen users with a family history of breast cancer.

Havens P.L., Perumean-Chaney S.E., Patki A., Cofield S.S., Wilson C.M., Liu N., Anderson P.L., Landovitz R.J., Kapogiannis B.G., Hosek S.G., and Mulligan K. (2019).

Changes in bone mass after discontinuation of pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine in young men who have sex with men: Extension phase results of Adolescent Trials Network Protocols 110 and 113.

Havens P.L., Tamhane A., Stephensen C.B., Schuster G.U., Gordon C.M., Liu N., Wilson C.M., Hosek S.G., Anderson P.L., Kapogiannis B.G., and Mulligan K. (2019).

Short communication: Association of vitamin D Insufficiency and protective tenofovir diphosphate concentrations with bone toxicity in adolescent boys and young men using tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis.

Mitchell R., Brown R., Fulton J., Alexander M., and Black S. (2019).

Do-it-yourself CDISC! A case study of Westat's successful implementation of CDISC standards on a fixed budget.

Lipman P.D., Dluzak L., and Stoney C.M. (2019).

Is this study feasible? Facilitating management of pragmatic trial planning milestones under a phased award funding mechanism.

Rohan E.A., Slotman B., Goettsche Tristani E., Townsend J.S., White D.E., Fultz-Butts K., and Gardner A. (2019).

Evaluating the feasibility of using a mobile app to track oncology patient navigation activities and outcomes.

Yeganeh N., Kerin T., Ank B., Watts D.H., Camarca M., Joao E.C., Pilotto J.H., Veloso V.G., Bryson Y., Gray G., Theron G., Dickover R., Morgado M.G., Santos B., Kreitchmann R., Mofenson L., and Nielsen-Saines K. (2018).

Human immunodeficiency virus antiretroviral resistance and transmission in mother-infant pairs enrolled in a large perinatal study.

Havens P.L., Stephensen C.B., Van Loan M.D., Schuster G.U., Woodhouse L.R., Flynn P.M., Gordon C.M., Pan C.G., Rutledge B., Harris D.R., Price G., Baker A., Meyer W.A., Wilson C.M., Hazra R., Kapogiannis B.G., Mulligan K., and Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 109 Study Team (2018).

Vitamin D3 supplementation increases spine bone mineral density in adolescents and young adults with human immunodeficiency virus infection being treated with tenofovir disoproxil fumarate: A randomized, placebo-controlled trial.

Havens P.L., Tamhane A., Stephensen C.B., Schuster G.U., Gordon C.M., Liu N., Wilson C.M., Hosek S.G., Anderson P.L., Kapogiannis B.G., and Mulligan K. (2018).

Association of vitamin D insufficiency and protective tenofovir diphosphate concentrations with bone toxicity in adolescent boys and young men using tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis.

Chung D.C., McCague S., Yu Z.F., Thill S., DiStefano-Pappas J., Bennett J., Cross D., Marshall K., Wellman J., and High K.A. (2018).

Novel mobility test to assess functional vision in patients with inherited retinal dystrophies.

Mollica M.A., Kent E.E., Castro K.M., Ellis E.M., Ferrer R.A., Falisi A.L., Gaysynsky A., Huang G., Palan M.A., and Chou W.S. (2018).

Perspectives on palliative care in cancer clinical trials: Diverse meanings from multidisciplinary cancer care providers.

Kapogiannis B.G., Wilson C.M., Price G.N., Harris D.R., Hazra R., Mulligan K., Havens P.L., Stephensen C.B., Flynn P.M., Rutledge B., Pan C.G., Woodhouse L.R., Van Loan M.D., Baker A., Gordon C.M., Shuster G.U., and Meyer W.A. (2018).

Vitamin D3 supplementation increases spine bone mineral density in adolescents and young adults with HIV infection being treated with tenofovir disoproxil fumarate: A randomized, placebo-controlled trial.

Mast A.E., Bialkowski W., Bryant B.J., Wright D.J., Birch R.J., Kiss J.E., D'Andrea P., Cable R.G., and Spencer B.R. (2016).

A randomized, blinded, placebo-controlled trial of education and iron supplementation for mitigation of iron deficiency in regular blood donors.

Gohagan J.K., Prorok P.C., Yurgalevitch S., Miller A.B., Feld R., Fontana R., Jatoi I., Lawrence W., Miller A., Rajput A., Sherman M., Welch G., Wright P., and Albertsen P. (2015).

Changes in and impact of the death review process in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Want to work with us?
You’ll be in great company.

About Us Careers

Westat Employees.
Westat Employee.
AAA Foundation for Traffic Safety
Baltimore Metropolitan Council
Centers for Disease Control and Prevention
Centers for Medicare & Medicaid Services
Chicago Metropolitan Agency for Planning
DC Public Schools
Georgia Department of Transportation
Internal Revenue Service
Leadership Montgomery
Maryland Cancer Registry
Michigan Department of Health and Human Services
National Science Foundation
NYC Mayor’s Office for Economic Opportunity
Organization for Economic Cooperation and Development
Robert Wood Johnson Foundation
SiriusXM
Social Security Administration
Substance Abuse and Mental Health Services Administration
Teach for America
Texas Education Agency
The Johns Hopkins University
The National Institutes of Health
The Verizon Foundation
Toyota
U.S. Department of Agriculture
U.S. Department of Education
U.S. Department of Health and Human Services
U.S. Department of Justice
U.S. Department of Transportation
U.S. Department of Veterans Affairs
University of Maryland Baltimore Campus
University of Michigan
University System of Maryland
Explore Our Clients

Please wait...

Forbes 2021 The Best Employers for Women Powered by StatistaForbes 2021 The Best Employers for Diversity Powered by StatistaForbes 2021: America's Best Midsize Employer Powered by Statista

Westat is an Equal Opportunity Employer and does not discriminate on the basis of race, creed, color, religion, sex, national origin, age, veteran status, disability, marital status, sexual orientation, citizenship status, genetic information, gender identity or expression, or any other protected status under applicable law. Notices to Employees & Applicants.